131 related articles for article (PubMed ID: 8961974)
41. Development and partial characterization of a human T-lymphoblastic leukemic (CCRF-CEM) cell line resistant to etoposide. Analysis of possible circumventing approaches.
Flandina C; Flugy A; Borsellino N; D'Alessandro N
J Chemother; 1996 Dec; 8(6):465-71. PubMed ID: 8981188
[TBL] [Abstract][Full Text] [Related]
42. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide.
Eymin B; Dubrez L; Allouche M; Solary E
Cancer Res; 1997 Feb; 57(4):686-95. PubMed ID: 9044846
[TBL] [Abstract][Full Text] [Related]
43. High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults.
Le Deley MC; Vassal G; Taïbi A; Shamsaldin A; Leblanc T; Hartmann O
Pediatr Blood Cancer; 2005 Jul; 45(1):25-31. PubMed ID: 15795880
[TBL] [Abstract][Full Text] [Related]
44. Reduced DNA ligase activity in etoposide resistant human lymphatic leukaemia CEM cells.
Fredriksson E; Liliemark E; Polischouk A; Soderhall S; Albertioni F; Ljungquist S
Biochem Pharmacol; 2002 Jan; 63(2):259-64. PubMed ID: 11841801
[TBL] [Abstract][Full Text] [Related]
45. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
46. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.
Winick NJ; McKenna RW; Shuster JJ; Schneider NR; Borowitz MJ; Bowman WP; Jacaruso D; Kamen BA; Buchanan GR
J Clin Oncol; 1993 Feb; 11(2):209-17. PubMed ID: 8426196
[TBL] [Abstract][Full Text] [Related]
47. Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation.
Jarvis WD; Johnson CR; Fornari FA; Park JS; Dent P; Grant S
J Pharmacol Exp Ther; 1999 Sep; 290(3):1384-92. PubMed ID: 10454518
[TBL] [Abstract][Full Text] [Related]
48. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
49. Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia.
Blanco JG; Dervieux T; Edick MJ; Mehta PK; Rubnitz JE; Shurtleff S; Raimondi SC; Behm FG; Pui CH; Relling MV
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10338-43. PubMed ID: 11526240
[TBL] [Abstract][Full Text] [Related]
50. Etoposide-induced cytotoxicity in two human T-cell leukemic lines: delayed loss of membrane permeability rather than DNA fragmentation as an indicator of programmed cell death.
Catchpoole DR; Stewart BW
Cancer Res; 1993 Sep; 53(18):4287-96. PubMed ID: 8364925
[TBL] [Abstract][Full Text] [Related]
51. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
52. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
53. Variable expression of p16 protein in patients with acute myeloid leukemia without gross rearrangements at the DNA level.
Jamal R; Thomas NS; Gale RE; Linch DC
Leukemia; 1996 Apr; 10(4):629-36. PubMed ID: 8618439
[TBL] [Abstract][Full Text] [Related]
54. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
55. Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: evidence of commitment to apoptosis rather than mitotic cell death.
Sleiman RJ; Stewart BW
Clin Cancer Res; 2000 Sep; 6(9):3756-65. PubMed ID: 10999770
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
57. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
58. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Anderson JR; Arthur D; Catalano PJ; Freidlin B; Heyn R; Khayat A; Krailo M; Land VJ; Miser J; Shuster J; Vena D
J Clin Oncol; 1999 Feb; 17(2):569-77. PubMed ID: 10080601
[TBL] [Abstract][Full Text] [Related]
59. Acute myelomonocytic leukemia after treatment with chronic oral etoposide: are MLL and LTG9 genes targets for etoposide?
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Inaba T; Fujita N; Moriguchi T; Yamamoto K; Seto M; Ueda R
Int J Hematol; 1994 Aug; 60(2):145-9. PubMed ID: 7948964
[TBL] [Abstract][Full Text] [Related]
60. [Mechanism of occurrence of secondary tumors by antitumor drugs].
Andoh T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):1988-98. PubMed ID: 10584562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
